Abstract
Polycystic kidney disease (PKD) is a common genetic disorder that results in a proliferating and enlarging cyst and ultimately leads to loss of kidney function. Because an enlarged cyst is a primary factor for limited kidney function, the large cyst is surgically removed by laparoscopic deroofing or sclerosant. This a relatively nascent treatment method entails complications and sometimes fail due to the cyst fluid refilling and infection. This study proposes using a more stable and effective polidocanol foam with glycerol and Rose Bengal (GRP form) to prevent cyst regeneration and irritation, which is caused by the required body movement during the treatment. Specifically, the foam retention time and viscosity were increased by adding glycerol up to 10% (w/v). The GRP form inhibited cellular proliferation and disrupted cellular junctions, e-cadherin, and cyst formation, demonstrated by the LDH, Live and Dead, and re-plating culture assays. The GRP foam was shown to be a safe and effective treatment as a commercial grade polidocanol foam form by an in vivo study in which subcutaneously injected mice injected with commercial 3% polidocanol, and the GRP foam showed no difference in inflammation. Thus, this study provides an advanced polidocanol form by adding glycerol and Rose-Bengal to help existing sclerotherapy.
Highlights
Polycystic kidney disease (PKD) is a systematic disorder, and patients suffer from innumerable cyst proliferation and enlargement from the age of thirty
3% was selected in this study, which is the highest administered dosage possible and exerts the most cytotoxic and membrane destabilizing effect on Madin-Darby Canine Kidney (MDCK) cells, producing more comparable results
MDCK, cyst forming cells that are used in PKD studies, was used to investigate the foam’s ability to debilitate MDCK cyst generation by direct treatment and re-plating experiments
Summary
Polycystic kidney disease (PKD) is a systematic disorder, and patients suffer from innumerable cyst proliferation and enlargement from the age of thirty. Multiple enlarged cysts lower kidney function and dramatically undermine patients’ quality of life through flanking abdominal pain, infected cyst, or hypertension [1]. Relieving the cystic burden is essential in improving the clinical progression and safeguarding the quality of life of patients. One method to ablate symptomatic renal cysts is sclerotherapy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
